Screening for Familial Gastric Cancer in First Degree Relatives

Malignant Neoplasm of Stomach Clinical Trial

— FamGaCan  

Official title:

Screening for Familial Gastric Cancer in First Degree Relatives

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01727908
• Other study ID #: Protocol ID 2012/270
• Status: Terminated
• Phase: N/A
• Start date: November 2012
• Est. completion date: September 2016

Study information

• Verified date: April 2017
• Source: Radboud University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether staining of the gastric mucosa increases the number of detected (pre)malignant foci of intestinal and diffuse type gastric cancer, in first degree relatives of individuals with familial gastric cancer.

Description:

Rationale:

Familial gastric cancer (FGC) concerns about 10% of all gastric cancers. It has an impressive impact on both emotional and physical wellbeing of first degree relatives of patients with (early) onset of gastric cancer. FGC can in 1-3% be attributed to one single hereditary syndrome, the hereditary diffuse gastric cancer (HDGC). HDGC is associated with a CDH1 mutation in about 40 % of the cases. In case there is no CDH1 mutation, referred to as familiar diffuse gastric cancer (FDGC), it remains uncertain how to guide and/or screen family members. The same applies for the rare familial intestinal type gastric cancer (FIGC).

Aim:

In this study we want to determine the value of endoscopic screening in members of families with FGC, both FDGC and FIGC. Also, we will analyze the associations of life style factors, including dietary habits with the development of FDGC, to be able to built preventive strategies. Finally, we want to assess the psychological impact of our screening protocol.

Objective:

Primary, to determine whether staining of the gastric mucosa increases the number of detected (pre)malignant foci of diffuse type gastric cancer, in individuals from families with FDGC as well as dysplastic, adenomatous and early intestinal cancers in individuals from families with FIGC. Secondary: A To determine the optimal pathological work-up the detection rate of (pre-)malignancy. B To determine clinical and life style factors that are associated with the two types of FGC. C To determine the psychosocial impact of the screening protocol in this population. D To develop a strategy for screening individuals from FGC families and creative advise for preventive measures.

Study design:

A randomized controlled trial included in a prospective cohort analysis.

Study population:

All (first degree) relatives , from 18 years and older from patients who fulfill the criteria for a FGC. These are; 1] all first degree relatives of an individual with diffuse gastric cancer, without proven CDH1 mutation, or members from families with 2] 2 or more individuals with gastric carcinoma, at least one < 50 yrs, or 3] 3 or more individuals with gastric carcinoma, any age, any type, or 4] 1 individual with any type gastric carcinoma < 40 yrs.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 79
• Est. completion date: September 2016
• Est. primary completion date: September 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• adult (= 18 yrs), female and male relatives

• fully legal competent (to simplify the common consent agreement for blood withdrawal, DNA analysis and serial endoscopies.)

• individuals that signed the common consent agreement

• first degree relative of an individual with diffuse gastric cancer from a FDGC-family, without proven mutation,

• OR: 2 or more individuals with gastric carcinoma, at least one < 50 yrs

• OR: 3 or more individuals with (diffuse/intestinal/other type) gastric carcinoma, any age

• OR 1 individual with any type gastric carcinoma < 40 yrs

Exclusion Criteria:

• immature individuals

• actual gastric ulcer or gastric bleeding

• previous diagnosis of gastric cancer

• hypersensitivity to Indigocarmine

• individuals with co-morbidity which might increase the sedation and/or endoscopy risk:

COPD Gold III/IV Cardiac failure Increased bleeding tendency or use of medication which increases bleeding tendency

Related Conditions & MeSH terms

• Adenocarcinoma
• Carcinoma, Diffuse Type
• Intestinal Type Adenocarcinoma of Stomach
• Malignant Neoplasm of Stomach
• Neoplasms
• Relative (Related Person)
• Stomach Neoplasms

Intervention

Other:
• Endoscopy with staining of the mucosa
Staining of the gastric mucosa with acetic acid and Indigocarmine

Locations

Country	Name	City	State
Netherlands	Department of Gastroenterology and Hepatology, Radboud University Nijmegen Medical Centre	Nijmegen	Po Box 9101

Sponsors (1)

Lead Sponsor	Collaborator
Radboud University

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The percentage of increasement of endoscopic detection of (pre)malignant for gastric cancer by staining of the gastric mucosa.		all patients will have a follow up of five years, during which four endoscopies will be performed
Secondary	To determine the optimal pathological work-up the detection rate of (pre-)malignancy, measured by the number of (pre) malignant foci found by the pathologist with different coloring and immunohistochemic techniques.		all patients will have a follow up of five years, during which four endoscopies with biopsy sampling will be performed
Secondary	To determine the association of clinical and life style factors with the two type of Familial Gastric Cancer, partly assessed from the patients'clinical files (eg BMI), partly by assessment of possible risk factors in blood (eg Helicobacter Pylori).		after three years of follow up these data will be assessed
Secondary	To determine the psychosocial impact of the screening protocol in this population, measured as the amount of stress and anxiety by use of the Hospital Anxiety and Distress Scale and the amount of cancer-worry by use of the Cancer Worry Scale.		during the follow up period of five years, each patient will receive questionaires at six time points. Assessment of these data will be performed after finishing the follow-up of the last patient, about six years after the start of this study.